Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Authors
Keywords
Brain tumor, Glioblastoma, Glioma, Targeted therapies
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 17, Issue 8, Pages -
Publisher
Springer Nature
Online
2016-06-23
DOI
10.1007/s11864-016-0418-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
- (2015) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Heat shock protein vaccines against glioblastoma: from bench to bedside
- (2015) Leonel Ampie et al. JOURNAL OF NEURO-ONCOLOGY
- Insulator dysfunction and oncogene activation in IDH mutant gliomas
- (2015) William A. Flavahan et al. NATURE
- Vaccination strategies for neuro-oncology: Table 1.
- (2015) John H. Sampson et al. NEURO-ONCOLOGY
- IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
- (2015) David A. Reardon et al. NEURO-ONCOLOGY
- ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY
- (2015) Hui K. Gan et al. NEURO-ONCOLOGY
- LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL
- (2015) W. Wick et al. NEURO-ONCOLOGY
- American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
- (2015) Quinn T. Ostrom et al. NEURO-ONCOLOGY
- Toward precision medicine in glioblastoma: the promise and the challenges
- (2015) Michael D. Prados et al. NEURO-ONCOLOGY
- Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas
- (2015) Ricky Chen et al. Neurosurgical Focus
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
- (2015) Jara Majuelos-Melguizo et al. Oncotarget
- Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
- (2014) H. Wakimoto et al. CLINICAL CANCER RESEARCH
- NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age
- (2014) G Kenneth Gray et al. Expert Review of Neurotherapeutics
- Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme
- (2014) Adam M Swartz et al. Immunotherapy
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
- (2014) J. Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
- (2014) B. Thaci et al. NEURO-ONCOLOGY
- Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
- (2014) Maciej M. Mrugala et al. SEMINARS IN ONCOLOGY
- Treating advanced melanoma: current insights and opportunities
- (2014) Michael Tronnier et al. Cancer Management and Research
- Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
- (2013) Amade Bregy et al. CANCER TREATMENT REVIEWS
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- (2013) Prakash Chinnaiyan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- A Tell-Tail Sign of Chromatin: Histone Mutations Drive Pediatric Glioblastoma
- (2012) Esther Rheinbay et al. CANCER CELL
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
- (2012) Dominik Sturm et al. CANCER CELL
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
- (2012) E. Q. Lee et al. NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now